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neutrophil elastase in sputum supernatant were also signifi-
cantly decreased in those treated with erythromycin com-
pared with the placebo group (p = 0.021 and p = 0.024,
respectively). The mean exacerbation rate was lower in
the erythromycin group than in the placebo group (relative 
risk = 0.554, p = 0.042). Kaplan-Meier survival analysis showed 
that erythromycin significantly delayed the time to the first 
COPD exacerbation compared with placebo (p = 0.032).  Con-
clusions: Erythromycin treatment in COPD patients can re-
duce airway inflammation and decrease exacerbations and 
may therefore be useful in the management of COPD. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Chronic obstructive pulmonary disease (COPD) is a 
common cause of morbidity and mortality worldwide  [1–
3] . It is characterized by persistent pulmonary inflamma-
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 Abstract 
 Background: Chronic obstructive pulmonary disease (COPD) 
is characterized by airway inflammation and is associated 
with acute exacerbations. Macrolide antibiotics have been 
shown to exhibit anti-inflammatory effects in some chronic 
airway inflammatory diseases.  Objective: The aim of this 
study was to assess the effect of treatment with erythromy-
cin on airway inflammation and health outcome in COPD pa-
tients.  Methods: We conducted a randomized, placebo-con-
trolled, double-blind trial of erythromycin for a period of 6 
months. Thirty-six COPD patients were randomized to treat-
ment with oral erythromycin (125 mg, three times/day) or 
placebo. The primary outcomes were neutrophil number in 
sputum and exacerbations.  Results: Thirty-one patients 
completed the study. At the end of treatment, neutrophil 
counts in the sputum were significantly decreased in the 
group treated with erythromycin compared with placebo-
treated patients (p = 0.005). Total cells in the sputum and 
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tion, which is thought to lead to progressive airflow lim-
itation. Exacerbations of COPD are associated with in-
creased lung inflammation and impair in the quality of 
life of patients  [4] . Thus therapeutic interventions to re-
duce lung inflammation may lead to improved outcome 
in COPD patients.
 Airway inflammation in COPD can be assessed by 
examination of cells and inflammatory mediators in in-
duced sputum  [5] . Smokers and exsmokers with COPD 
have increased sputum neutrophil numbers compared 
with subjects without COPD, which increase further 
during exacerbations. Increased sputum neutrophils 
have been associated with a more rapid decline in forced 
expiratory volume in 1 s (FEV 1 )  [6–8] . Furthermore, 
neutrophil activation markers, e.g. neutrophil elastase 
(NE), myeloperoxidase and lactoferrin, are elevated in 
sputum supernatants of COPD subjects  [9] , suggesting 
that neutrophils are active participants in airway in-
flammation.
 Inflammation in COPD lungs is largely resistant to 
therapy with corticosteroids and consequently alterna-
tive approaches of anti-inflammatory therapy are needed 
 [10, 11] . Long-term treatment with macrolides is an ac-
cepted and effective treatment in some chronic lung dis-
eases  [12] , especially for diffuse panbronchiolitis (DPB) 
 [13] . Beneficial effects of macrolides have also been shown 
in other airway inflammatory diseases such as cystic fi-
brosis  [14, 15] , bronchiectasis  [16] , and bronchial asthma 
 [17, 18] . The mechanisms by which macrolides exert a 
beneficial effect on chronic inflammatory airway disease 
are thought to be independent of their antibiotic effects 
but rather due their anti-inflammatory effects. These in-
clude inhibition of cytokine production by neutrophils, 
monocytes and bronchial epithelial cells  [19–21] . Treat-
ment with erythromycin has been shown to reduce the 
number of neutrophils and the levels of interleukin-8 (IL-
8) protein in bronchoalveolar lavage fluid from patients 
with DPB and cystic fibrosis  [10, 21–24] . We and others 
have shown that the anti-inflammatory effects of eryth-
romycin and clarithromycin are associated with inhibi-
tion of the transcription factors activator protein-1 and 
nuclear factor-  B  [25, 26] .
 The effects of macrolide treatment on lung inflamma-
tion in COPD patients have not been studied. We there-
fore conducted a randomized, double-blind, placebo-
controlled trial of erythromycin (125 mg three times a 
day) in COPD patients to assess its effects on sputum cell 
counts and health outcome in COPD patients.
 Materials and Methods 
 Patients 
 We recruited patients meeting the GOLD diagnostic criteria 
for COPD  [27] . Patients were  6 40 years old; had a diagnosis of 
COPD, an FEV 1 between 30 and 70% of predicted, FEV 1 /(forced 
vital capacity) FVC  ! 0.7, and FEV 1 reversibility  ! 15% and/or 
 ! 200 ml to   2 -agonists, and were past or present cigarette smok-
ers with at least a 10 pack-year smoking history. Patients were 
studied when clinically stable for at least 1 month following an 
exacerbation. Patients with significant respiratory disease other 
than COPD were excluded. Patients were also excluded if there 
was a history of unstable cardiovascular disorders or hypersensi-
tivity to macrolides. During the study period, no change in any 
therapy with anti-inflammatory activity was allowed unless there 
was clinical necessity, in which case the patient was excluded from 
the study. Patients gave written informed consent to participate, 
and the study was approved by the Ethics Committee of the First 
Affiliated Hospital of Guangxi Medical University.
 Study Design 
 Patients had a 1-month run-in period free of exacerbation 
symptoms before baseline sampling. Eligible participants were 
randomly assigned to receive oral erythromycin (125 mg three 
times a day, enteric-coated tablets; DaLian Metro Pharmaceutica, 
China) or placebo for 6 months. Spirometry, quality of life, exac-
erbations, and sputum assessment for cell counts and inflamma-
tory markers were recorded at 0 (baseline), 3 and 6 months. The 
co-primary outcomes for this study were sputum neutrophil 
numbers and exacerbations. Treatment adherence was encour-
aged by calls from the study coordinator and measured by pill 
counts.
 Analysis of Sputum Samples 
 Induced sputum was performed according to a standard tech-
nique, as previously described  [5] . The collected sputum was dis-
persed using dithiothreitol. Total and differential counts of in-
flammatory cells were performed and sputum supernatant was 
stored. The NE level in the supernatant of induced sputum was 
assessed by enzyme-linked immunosorbent assay kits (Human 
PMN-Elastase ELISA, Bender MedSystems, Austria). Sputum 
bacterial culture was performed at baseline and after 6 months of 
treatment. 
 Quality of Life 
 Health status was measured using the SGRQ and the Short 
Form 36-item Questionnaire (SF-36) at baseline, and after 3 and 
6 months  [28, 29] .
 Monitoring and Definition of Exacerbation 
 The severity of an exacerbation was graded as follows: a mod-
erate exacerbation was defined as a sustained worsening of base-
line respiratory symptoms for at least 2 days that required in-
creased treatment or additional therapy such as oral corticoste-
roids or antibiotics. A severe exacerbation was defined as above 
but with the requirement for admission to hospital. Information 
on exacerbations was collected during clinic visits, and any pa-
tient experiencing worsening respiratory symptoms was instruct-
ed to contact the investigator immediately and report to the study 
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number of moderate-severe exacerbations over the 6-month fol-
low-up period.
 Monitoring Adverse Events 
 At entry and trial completion, a 12-lead electrocardiograph, 
blood pressure measurements and physical examination were 
performed. Routine biochemistry and hematology testing were 
also assessed at study entry, and after 3 and 6 months. The pres-
ence of adverse events, including the presence of fever, headache, 
nausea, vomiting, diarrhea and skin rashes, was recorded at each 
study visit.
 Statistical Analysis 
 The final analysis was conducted on an intention-to-treat ba-
sis using SPSS software (version 16.0). Data were expressed as 
means, standard deviations and 95% confidence intervals unless 
otherwise stated. A p value  ! 0.05 was considered significant (two-
tailed tests).
 Comparison of the baseline data between both groups was an-
alyzed using the two-sample t test. Serial stable lung function, 
total cells and NE in sputum, and SGRQ and SF-36 data at base-
line, and after 3 and 6 months were compared by linear mixed-
model analysis with visit number as the repeated measure. A sim-
ilar linear mixed model was used to examine differences between 
erythromycin and placebo groups.
 The number of exacerbations was analyzed using a general-
ized linear model for a Poisson distribution (expressed as mean 
rate, i.e. mean number of exacerbations per patient in 6 months). 
The number of moderate-severe exacerbations was used as the 
dependent outcome variable, using the logarithm of time on treat-
ment as an offset variable and the smoking index, sex, percent of 
predicted FEV 1 at baseline and age as covariates. The time to first 
exacerbation between the placebo and macrolide groups was ana-
lyzed by Kaplan-Meier survival analysis.
 Results 
 Fifty-five patients were screened for the study, and 36 
were eligible for study entry ( fig. 1 ). Of these 36 patients, 
18 were assigned to receive placebo and 18 were assigned 
to erythromycin. Thirty-one of the randomized patients 
completed the study; 3 in the placebo group and 2 in the 
erythromycin group withdrew ( fig. 1 ).
 Demographic Data 
 There were no significant differences between both 
study groups at baseline with respect to age, gender, lung 
function, smoking history and body mass index. Virtu-
ally all patients received at least one respiratory medica-
tion, and respiratory medication use was similar in the 
two treatment groups ( table 1 ).
 Sputum Cell Counts and NE 
 Baseline total sputum counts and differential cell 
counts were similar between the two groups ( table  2 ). 
Treatment with erythromycin significantly decreased 
the total number of cells from baseline to months 3 and 
6 (p = 0.005 and p = 0.004, respectively). This reduction 
was also significantly greater compared with placebo
(p = 0.021). Erythromycin also produced a similar reduc-
tion in neutrophil cell counts from baseline to months 3 
and 6 (p = 0.002 and p = 0.001, respectively;  table 2 ). This 
decrease was significantly different compared with pla-
cebo treatment (p = 0.005). In contrast, the number of 
Treatment discontinuation (n = 3) due to
worsening of symptoms (n = 2)
Unknown cause (n = 1)
Treatment discontinuation (n = 2) due to
complication: left heart failure (n = 1)
Erythromycin side effect (n = 1)
Enrolment = 56
Completed n = 15 Completed n = 16
Allocated = 36
Withdrawn n = 19
Erythromycin n = 18Placebo n = 18
 Fig. 1. Study profile: all patients were en-



















   
   
   
   
   
   
   
   
   



















 He  /Ou  /Zhang  /Bai  /Liu  /Li  /Deng  /
MacNee  /Zhong  
 Respiration 2010;80:445–452 
 
448
lymphocytes and macrophages did neither significantly 
change during treatment nor between the two groups. 
Erythromycin treatment significantly reduced NE con-
centrations in sputum supernatant compared with base-
line (p = 0.027 after 3 months and p = 0.015 after 6 
months). This reduction was also significantly greater 
compared with 6-month placebo treatment (p = 0.024; 
 fig. 2 ).
 Sputum Bacteriology 
 At baseline, 16 stable COPD patients (placebo = 7/
erythromycin = 9) had bacterial growth in the sputum, of 
which 4 patients had more than one organism. The main 
three bacterial pathogens in the sputum were  Streptococ-
cus pneumoniae (placebo = 3/erythromycin = 3),  Hae-
mophilus influenzae (placebo = 3/erythromycin = 2) and 
 Branhamella catarrhalis (placebo = 2/erythromycin = 2). 
At the 6-month time point, 14 sputum samples from the 
patients had significant bacterial growth and 3 of these 
specimens had growth of more than one organism. The 
main three pathogens that were detected were  S. pneu-
moniae (placebo = 3/erythromycin = 2),  H. influenzae 
(placebo = 2/erythromycin = 2) and  B. catarrhalis (pla-
cebo = 2/erythromycin = 1). There was no difference in 
the detection rate regarding the three main microorgan-
isms between the two groups at baseline or after 6 months 
of treatment.
 Health-Related Quality of Life 
 SF-36 and SGRQ scores were not significantly differ-
ent at baseline between the placebo and erythromycin 
groups. In the erythromycin group, general health scores 










































 Fig. 2. Effect of erythromycin on induced sputum NE concentra-
tion (ng/ml) in COPD patients at baseline and after 3 and 6 
months of treatment (p = 0.024, erythromycin vs. placebo after 6 
months of treatment). 
 Fig. 3. Kaplan-Meier curves showing the proportion of patients 
without an exacerbation (cumulative survival analysis) versus 
time to the first exacerbation for the placebo and erythromycin 
groups (p = 0.032). 
Table 1.  Demographic and baseline characteristics
Parameters Placebo Erythromycin
Patients, n 18 18
Age, years 69.387.1 68.888.1
Males, n (%) 16 (88.9) 15 (83.3)
FEV1, liters 1.0280.41 1.1280.47
FEV1, % of predicted 42.1818.6 44.3817.9
FVC, liters 2.4880.8 2.3780.7
FEV1/FVC, % 48.688.4 46.988.0
Smoking, pack-years 41.1819.8 42.3817.9
Body mass index 23.283.1 23.483.6
Present treatment, n (%)
Inhaled corticosteroid 8 (44.4) 7 (38.8)
Theophylline 11 (61.1) 10 (55.6)
Inhaled anticholinergic 9 (50) 10 (55.6)
Inhaled -adrenergic 13 (72.2) 14 (77.8)
M eans 8 SD and numbers (%) are shown. No significant dif-
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and 6 months (p = 0.02) compared with baseline ( table 3 ). 
Similarly, there was also a significant reduction in social 
functioning scores after 3 and 6 months compared with 
baseline (p = 0.045 and p = 0.044, respectively). However, 
these changes were not significantly different between 
the erythromycin and placebo groups.
 For the other SF-36 scores including physical func-
tioning, pain index, vitality, physical role limitation, 
emotional role limitation and mental health, there were 
no significant changes in either group ( table  3 ). There 
were also no significant changes in SGRQ scores in either 
group ( table 3 ).
 Exacerbations 
 There were a total of 31 moderate-severe exacerbations 
over the 6-month treatment time, of which 20 occurred 
in the placebo group and 11 in the erythromycin group. 
The proportion of patients with at least one exacerbation 
was 78% in the placebo group and 50% in the erythromy-
cin group. Patients who received erythromycin treatment 
experienced a mean of 0.61 exacerbations (95% confi-
dence interval: 0.42–0.80) per patient/6-month follow-
up, compared with 1.11 (0.83–1.39) exacerbations in the 
placebo group (p = 0.042), with a relative risk of an exac-
erbation in the erythromycin group of 0.554 compared 
with the placebo group ( table 4 ). Exacerbations occurring 
during the study were more frequent in patients with low-
er FEV 1 % of predicted. Sex, age and smoking index did 
not affect exacerbation frequency.
 The median time to the first exacerbation was 86 days 
in the placebo group and 155 days in the erythromycin 
group. Kaplan-Meier survival analysis showed that eryth-
Table 2.  Effects of erythromycin on inflammatory cells (106/ml) in induced sputum
Parameters Placebo E rythromycin p value
vs.
placebobaseline 3 months 6 months baseline 3 months 6 months
Total cells 3.76 (3.26–4.26) 3.73 (3.24–4.20) 3.69 (3.22–4.15) 3.74 (3.24–4.24) 3.19 (2.84–3.53)* 3.20 (2.81–3.59)* 0.021
Neutrophils 2.81 (2.44–3.19) 2.79 (2.44–3.13) 2.75 (2.44–3.07) 2.80 (2.40–3.20) 2.29 (1.87–2.70)* 2.25 (1.90–2.60)* 0.005
Macrophages 0.71 (0.60–0.82) 0.75 (0.64–0.86) 0.72 (0.60–0.83) 0.70 (0.58–0.82) 0.66 (0.54–0.78) 0.69 (0.50–0.89) 0.296
Lymphocytes 0.22 (0.17–0.27) 0.21 (0.15–0.26) 0.20 (0.14–0.26) 0.20 (0.17–0.23) 0.19 (0.16–0.21) 0.19 (0.15–0.23) 0.946
Me ans and 95% confidence intervals are shown. * p < 0.001 vs. baseline in the erythromycin group.
Table 3.  Effects of erythromycin on SF-36 and SGRQ scores in COPD
Parameters Placebo E rythromycin
baseline 3 months 6 months baseline 3 months 6 months
SF-36
General health 40.0 (30.7–49.3) 38.3 (29.8–46.8) 39.8 (30.6–48.9) 37.2 (28.4–46.1) 40.1 (29.5–50.8)* 45.1 (34.7–55.5)*
Physical functioning 59.7 (48.8–70.7) 59.2 (49.0–69.3) 57.6 (47.3–67.9) 61.1 (51.3–70.9) 64.0 (53.7–74.3) 65.0 (55.2–74.8)
Bodily pain 80.7 (71.3–90.1) 79.9 (71.7–88.2) 80.4 (71.2–89.6) 79.9 (70.8–89.0) 77.2 (69.0–85.5) 80.4 (71.1–89.7)
Vitality 68.1 (61.3–74.8) 64.1 (57.0–71.2) 64.1 (56.6–71.6) 68.1 (60.4–75.7) 69.0 (61.9–76.1) 66.1 (56.0–76.2)
Role physical 45.8 (21.6–70.1) 41.0 (18.2–63.8) 46.2 (21.6–70.8) 44.4 (20.5–68.4) 48.2 (27.9–68.6) 45.1 (21.3–68.8)
Role emotional 59.3 (48.6–69.9) 59.6 (49.4–69.9) 60.0 (48.6–71.4) 59.3 (41.7–76.8) 63.6 (44.4–82.7) 63.4 (45.4–81.5)
Social functioning 60.2 (48.3–72.1) 59.1 (47.9–70.3) 58.8 (45.9–71.7) 62.7 (51.7–73.7) 70.7 (58.2–83.2)* 70.5 (57.6–83.4)*
Mental health 76.0 (65.9–86.1) 75.0 (66.5–85.6) 76.5 (67.2–85.8) 75.3 (65.4–85.2) 80.7 (73.8–87.6) 80.0 (70.7–89.3)
SGRQ
Total score 50.3 (43.1–57.5) 50.4 (42.9–57.9) 50.7 (42.9–58.6) 49.7 (41.8–57.6) 48.1 (39.0–57.1) 47.7 (38.4–56.9)
Symptom 66.3 (62.0–70.5) 64.0 (58.1–69.8) 66.3 (60.4–72.2) 67.5 (59.1–76.0) 64.5 (55.1–73.9) 64.0 (55.2–72.9)
Activity 56.1 (53.5–58.7) 55.0 (52.4–57.6) 55.6 (51.7–59.4) 57.3 (51.9–62.7) 54.9 (46.5–63.3) 53.5 (45.8–61.1)
Impact 36.3 (34.5–38.2) 35.0 (33.3–36.7) 36.5 (33.2–39.8) 35.6 (25.7–45.4) 37.6 (27.8–47.4) 38.4 (28.5–48.3)



















   
   
   
   
   
   
   
   
   



















 He  /Ou  /Zhang  /Bai  /Liu  /Li  /Deng  /
MacNee  /Zhong  
 Respiration 2010;80:445–452 
 
450
romycin significantly delayed the time to the first COPD 
exacerbation compared with placebo (p = 0.032; log-rank 
test;  fig. 3 ).
 Safety 
 Five patients dropped out of the study. In the erythro-
mycin group, 2 patients discontinued their participation 
in the study, 1 patient because of abdominal pain after 
erythromycin treatment and the other had a complica-
tion of left heart failure. In the placebo group, three pa-
tients dropped out of the study, 2 patients because of re-
spiratory insufficiency and another due to an unknown 
cause. In none of the participants was treatment associ-
ated with laboratory or ECG abnormalities.
 Discussion 
 This randomized controlled trial in COPD patients 
showed beneficial effects of erythromycin therapy on air-
way inflammation, exacerbations and health status. A re-
cent clinical trial reported a decrease in exacerbations in 
COPD patients treated with erythromycin  [30] . Our data 
not only confirm these results but also show that eryth-
romycin treatment reduced airway inflammation, as 
shown by a decreased number of neutrophils and neutro-
phil activity in sputum.
 COPD is a chronic inflammatory process, and neutro-
phils are considered to be a key player in this process. 
Neutrophils are elevated in the sputum of COPD patients 
 [8] . They are ascribed an active role in the disease process 
and are associated with an accelerated decline in FEV 1 
 [6, 7] . Neutrophils contribute to the pathogenesis of 
COPD by the production of proteases, oxidants and in-
flammatory mediators. Therefore, interventions that re-
duce neutrophil recruitment might be anticipated to 
modify the progression of COPD.
 The aim of this study was to investigate whether eryth-
romycin is effective in suppressing airway inflammation 
and neutrophil activity in COPD patients. Induced spu-
tum is a technique that has been used to investigate cel-
lular and cytokine changes in response to oral and in-
haled steroids. The present study showed a reduction in 
the total cell number in sputum, accounted for by a reduc-
tion in neutrophils, after erythromycin treatment. Treat-
ment with erythromycin also significantly reduced NE 
concentration in sputum supernatant, suggesting dimin-
ished airway neutrophil activation following treatment. 
This may also induce a beneficial effect by reducing pro-
teolytic damage in the airways. Reductions in neutrophil 
numbers and NE concentrations have been reported fol-
lowing macrolide treatment in patients with other chron-
ic airway diseases, such as DPB, bronchiectasis  [24] and 
asthma  [17] . One mechanism by which erythromycin may 
reduce neutrophil numbers is via improved phagocytosis 
of apoptotic cells. Alveolar macrophages treated with 
macrolide antibiotics show increased phagocytic capacity 
for apoptotic neutrophils  [31] and epithelial cells  [32] .
 The SGRQ and the SF-36 are the most commonly used 
to assess health status in clinical trials on COPD patients. 
However, there was no significant improvement in SGRQ 
scores and most domains of SF-36 following erythromy-
cin treatment except for social functioning scores and 
general health scores compared with placebo.
 We found the exacerbation rate was significantly de-
creased in patients treated with erythromycin compared 
with the placebo group. The relative risk of a moderate-
severe exacerbation was reduced by 35% in the erythro-
mycin group compared with the placebo group. The 
mechanism by which macrolides affect COPD exacerba-
tion frequency is still unknown. In vitro studies of mac-
rolides have shown a reduction in cellular inflammatory 
responses at the nuclear level  [25, 26] .
 Other studies have shown similar results with macro-
lides regarding the reduction of exacerbations  [30, 33] 
and decreased inflammatory cytokines in sputum  [34] . 
However, there are also some conflicting results showing 
a negative effect of macrolides on health status, sputum 
inflammatory cytokines and exacerbations  [35, 36] . The 
Table 4.  Analysis of exacerbation frequency and exacerbation du-
ration in 36 COPD patients with Poisson distribution
Parameters Relative
risk
9 5% CI p
valuelo wer upper
Erythromycin 0.554 0.314 0.979 0.042
Male sex 0.475 0.205 1.101 0.082
Regression 
coefficient
Age 0.036 –0.015 0.088 0.166
FEV1: % at baseline –0.049 –0.081 –0.017 0.005
Smoking: pack-years –0.007 –0.022 0.008 0.993
CI  = confidence interval. Relative risk and regression coeffi-
cients (B) (generalized linear model) are shown for binary vari-
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reason for these conflicting results is unknown, but may 
be due to differences in the study design, including the 
use of clarithromycin rather that erythromycin in these 
studies  [35, 36] . In our study and most previous studies 
with positive results  [30, 33] , it has been shown that at 
least 6 months of macrolide treatment can have beneficial 
effects, particularly on COPD exacerbations, effects be-
ing similar to those observed following long-term macro-
lide treatment of patients with DPB and cystic fibrosis 
 [14] . The reduction in exacerbations in our study was 
greater than that shown in the study by Seemungal et al. 
 [30] and less than that shown in the study by Suzuki et al. 
 [33] . Apart from differences in the study design, it is in-
teresting to note that the use of inhaled corticosteroid was 
different between these two studies, with the study by 
Seemungal et al.  [33] having the most and the study by 
Suzuki et al.  [30]  having the least number of patients con-
comitantly on inhaled corticosteroids, which may have 
influenced the differences in the magnitude of the reduc-
tion in exacerbation frequency between these studies. 
However, although erythromycin treatment decreased 
exacerbations of COPD, health status did not improve, 
which is surprising given the significant effect that exac-
erbations have in reducing health status.
 Our study has some limitations. The sample size was 
small and a 6-month treatment duration may be insuffi-
cient to assess exacerbation rate completely. Larger and 
longer studies with erythromycin will be required to de-
termine if these positive effects can be replicated.
 Previous studies have shown that lower airway bacte-
rial colonization in patients with COPD is related to ex-
acerbation frequency  [37–39] . One possible explanation 
for the improvement in exacerbations with erythromycin 
may result from its antibacterial effect. However, no sig-
nificant differences were found in the number of positive 
sputum cultures for the main COPD pathogens during 
the 6-month treatment between the two groups. A posi-
tive bacterial culture was found in 42% of stable COPD 
patients before treatment and in 45% after treatment, val-
ues of bacterial colonization that are in agreement with 
those in other studies  [37–39] .
 In summary, we have shown beneficial effects of 
erythromycin treatment in COPD patients, i.e. reduc-
tions in the number of neutrophils and in the NE concen-
tration in the sputum concomitant with a significant re-
duction in COPD exacerbations. These results will con-
firm the potential useful benefit of macrolide therapy in 
the management of COPD patients.
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